All Cholangiocarcinoma. articles
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
NewsAdvancing personalised medicine with a cholangiocarcinoma model
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.